Analysis
Apnimed, a Shionogi-backed biotech developing what could become the first FDA-approved pill for obstructive sleep apnea, launched its IPO terms Monday, offering 10 million shares at $14 to $16 to raise up to $150 million to $160 million. At the $15 midpoint, the Cambridge, Massachusetts-based company would carry a fully diluted market value of roughly $665 million.
Apnimed's sole clinical candidate, AD109 (Oxnimbi), is a fixed-dose combination of a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor designed to improve upper airway muscle activity and prevent airway collapse during sleep -- an oral alternative to the CPAP machines and surgical interventions that dominate sleep apnea treatment today. The drug has been studied in roughly 1,300 patients across multiple Phase 3 trials, and the company submitted its New Drug Application to the FDA in April 2026.
“The drug has been studied in roughly 1,300 patients across multiple Phase 3 trials, and the company submitted its New Drug Application to the FDA in April 2026.”
A pill-based treatment for obstructive sleep apnea would address a genuinely underserved market: CPAP compliance rates are notoriously poor, and Apnimed's oral approach could open treatment to patients who can't or won't tolerate existing options. BofA Securities, Evercore ISI and Cantor Fitzgerald are running the book, with pricing expected the night of Thursday, July 30, ahead of a Friday, July 31 debut on the Nasdaq under ticker APMD.
The listing adds a biotech name to a US IPO market that's leaned heavily on healthcare and biotech deals this cycle even as broader tech IPO activity concentrates in AI-infrastructure megadeals; Renaissance Capital data shows 208 IPOs have priced in the US so far in 2026, running about 6% ahead of the same point in 2025.
What to watch: whether Apnimed prices within its stated range given the crowded late-July IPO calendar, and whether the FDA acts on the AD109 NDA on a timeline that could validate the commercial thesis before the stock's early lockup periods expire.
